TCRX•TScan Therapeutics' third-quarter revenue fell sharply after its Amgen collaboration ended in August 2026, while its net loss narrowed slightly to $33.09 million. The company said its existing cash resources are expected to fund operations into the fourth quarter of 2027.
TScan reported $586,000 in third-quarter collaboration and license revenue and a net loss of $33.09 million. Research and development expenses fell due to lower spending on laboratory supplies and contracted services, as well as a prior workforce reduction. The company reorganized to focus on in vivo TCR-T therapies for solid tumors and paused enrollment in the Phase 3 ALLOHA-2 trial. It expects to file its first solid-tumor IND in the third quarter of 2027 and dose the first patient in the fourth quarter of 2027.
